2 型糖尿病患者与各种癌症患者的血清 CA199 水平升高。
Elevated serum CA199 levels in patients suffering type 2 diabetes vs. various types of cancer.
机构信息
Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical University, No. 950 Donghai Street, Fengze District, Quanzhou City, Fujian Province, 362000, China.
出版信息
BMC Endocr Disord. 2024 Jan 12;24(1):9. doi: 10.1186/s12902-024-01539-y.
AIMS
Carbohydrate antigen 199 (CA199) is a standard tumor marker, and recent studies have found elevated in CA199 levels in patients with diabetes. However, there is no systematic measurement and comparison of serum CA199 levels in patients with diabetes and cancer. Here, a detailed description of the changes in serum CA199 levels in patients with type 2 diabetes and various cancers was explored.
METHODS
A total of 5,641 participants were screened for clinical laboratory test results of serum CA199 levels over the past three years (2020-2023). This study included 2,464 healthy controls, 688 patients with type 2 diabetes, and 2,489 patients with 16 different types of cancer. Each type of cancer had more than 30 independent serum CA199 level test results. The serum CA199 levels were compared between cancer groups, type 2 diabetes patients, and healthy controls. Additionally, the CA199 levels of cancer patients were compared with those of patients with type 2 diabetes.
RESULTS
The serum CA199 levels of esophagus cancer, lung cancer, pancreatic cancer, ovarian cancer, breast cancer, rectum cancer, prostate cancer, bladder cancer, liver cancer, gastric cancer, cervical cancer, colon cancer, lymphoma, thyroid cancer, intracranial tumors, and nasopharyngeal laryngeal cancer were found to be elevated compared to healthy controls (P < 0.01). In addition, the serum CA199 levels of patients with type 2 diabetes were also significantly elevated compared to healthy controls (P < 0.01). Moreover, the degree of elevation in serum CA199 levels in patients with type 2 diabetes was not significantly different from that observed in some types of cancer, such as esophagus cancer (P = 0.163), breast cancer (P = 0.927), prostate cancer (P = 1.000), bladder cancer (P = 0.406), Lymphoma (P = 0.975), thyroid cancer (P = 1.000), intracranial tumors (P = 0.161), nasopharyngeal and laryngeal cancer (P = 1.000).
CONCLUSIONS
Serum CA199 levels also increase in type 2 diabetes, and the magnitude of the increase is similar to that seen in some cancers.
目的
糖类抗原 199（CA199）是一种标准的肿瘤标志物，最近的研究发现糖尿病患者的 CA199 水平升高。然而，目前尚无系统的方法来测量和比较糖尿病患者和癌症患者的血清 CA199 水平。在这里，详细描述了 2 型糖尿病患者和各种癌症患者血清 CA199 水平的变化。
方法
对过去三年（2020-2023 年）的临床实验室检测结果进行了 5641 名参与者的血清 CA199 水平筛查。本研究包括 2464 名健康对照者、688 名 2 型糖尿病患者和 2489 名患有 16 种不同类型癌症的患者。每种癌症都有 30 多个独立的血清 CA199 水平检测结果。比较了癌症组、2 型糖尿病患者和健康对照组之间的血清 CA199 水平。此外，还比较了癌症患者的 CA199 水平与 2 型糖尿病患者的 CA199 水平。
结果
食管癌、肺癌、胰腺癌、卵巢癌、乳腺癌、直肠癌、前列腺癌、膀胱癌、肝癌、胃癌、宫颈癌、结肠癌、淋巴瘤、甲状腺癌、颅内肿瘤和鼻咽癌患者的血清 CA199 水平均高于健康对照组（P<0.01）。此外，2 型糖尿病患者的血清 CA199 水平也明显高于健康对照组（P<0.01）。此外，2 型糖尿病患者血清 CA199 水平的升高程度与某些癌症类型（如食管癌、乳腺癌、前列腺癌、膀胱癌、淋巴瘤、甲状腺癌、颅内肿瘤、鼻咽癌）的升高程度无显著差异（P=0.163、P=0.927、P=1.000、P=0.406、P=0.975、P=1.000、P=0.161、P=1.000）。
结论
2 型糖尿病患者的血清 CA199 水平也升高，其升高幅度与某些癌症相似。
Zotero 插件